Biotech
Generate Biomedicines
Generate Biomedicines raises $370M Series C at $2B valuation
$370M
Total Raised
Series C
Latest Round
2018
Founded
200+
Employees
1 Main Street, Cambridge, MA 02142
1 min read
Quick Facts
Valuation
$2B
Latest Round Size
$370M
Latest Round Date
November 2024
Generate Biomedicines: Series C Funding Round
Generate Biomedicines has successfully raised $370M in Series C funding, reaching a valuation of $2B.
Company Overview
Generative biology AI drug discovery
Funding Details
The Series C round was led by Flagship Pioneering, with participation from T. Rowe Price, Fidelity, NVIDIA, Alaska Permanent Fund.
Company Information
- Headquarters: 1 Main Street, Cambridge, MA 02142
- Founded: 2018
- Employees: 200+
- Category: Biotech
Investment
Generate Biomedicines plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in Series C
- T. Rowe Price: Verified investor in Series C
- Fidelity: Verified investor in Series C
- NVIDIA: Verified investor in Series C
- Alaska Permanent Fund: Verified investor in Series C
Key Investors
Flagship Pioneering
Lead Investor
Verified investor in Series C
T. Rowe Price
Investor
Verified investor in Series C
Fidelity
Investor
Verified investor in Series C
NVIDIA
Investor
Verified investor in Series C
Alaska Permanent Fund
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M